Cancer vaccines market seen reaching $31.13 billion by 2035

The global cancer vaccines market is projected to grow from $11.31 billion in 2025 to $31.13 billion by 2035, driven by HPV elimination efforts, personalized mRNA vaccines and faster regulatory reviews. North America leads today, while Asia-Pacific is expected to grow fastest over the next decade.

Why it matters: - The cancer vaccines market is moving from a public-health niche toward a broader oncology platform. - Market Research Future projects the market will nearly triple by 2035, creating room for both preventive HPV products and newer therapeutic vaccines. - Growth matters because demand is being pulled by government immunization programs, cancer-screening plans and combination cancer therapies.

What happened: - Market Research Future said the global cancer vaccines market is projected to rise from USD 11.31 billion in 2025 to USD 31.13 billion by 2035. - The forecast implies a 10.72% compound annual growth rate from 2026 to 2035. - The first year of the forecast period, 2026, is valued at USD 12.45 billion. - The company tied the outlook to cervical cancer elimination mandates, individualized mRNA vaccine development and accelerated regulatory pathways. - The firm also published free sample and customization request links for the report: Request a free sample and Request customization.

The details: - WHO targets require 90% of girls to receive all recommended vaccinations by age 15 by 2030. - That target has pushed 144 nations to implement routine HPV schedules. - Australia’s single-dose schedule has shown efficacy while cutting procurement costs in half. - Market Research Future said that change opened about USD 600 million in additional Gavi-financed volume between 2023 and 2025. - Individualized mRNA programs can now sequence tumor and germline DNA, score up to 34 patient-specific epitopes and create a custom construct in six weeks. - Phase IIb adjuvant melanoma data showed a 44% decrease in recurrence risk when personalized mRNA vaccines were combined with anti-PD-1 therapy. - The report said that single readout moved an estimated USD 2.3 billion of 2024–2025 capital into customized programs. - Breakthrough Therapy and PRIME designations shorten review timelines by an average of 4.7 months. - Japan’s Sakigake framework offers similar regulatory relief. - Regulators are accepting platform-level manufacturing dossiers, allowing sponsors to validate one process rather than one product. - Roughly 61% of active oncology vaccine trials registered in 2025 included a checkpoint inhibitor or cytokine partner.

Between the lines: - The market is still anchored by preventive vaccines, but the fastest growth is shifting to therapeutic and personalized products. - Combination use with checkpoint inhibitors suggests vaccines are being positioned as part of broader oncology regimens, not standalone treatments. - The concentration of revenue in a few legacy HPV franchises leaves room for newer platform players to gain share if clinical and manufacturing data keep improving. - Asia-Pacific’s faster growth reflects lower-cost manufacturing and public-sector rollout, while North America remains the largest revenue base.

What's next: - The report expects computational antigen design to replace rule-based methods by 2030 for most personalized constructs. - It sees off-the-shelf shared-antigen libraries as a lower-cost path for recurrent mutations such as KRAS G12D. - It expects more royalty-based platform licensing deals, including upfront payments of USD 40 million to USD 120 million and milestones above USD 1 billion. - The outlook also points to decentralized regional micro-factories that could reduce vein-to-vein time below 14 days. - The report says emerging-market volume capture in countries including India, Indonesia, Nigeria and Vietnam could become a major demand source as lower-priced domestic products expand access.

The bottom line: - Cancer vaccines are transitioning from mass immunization products to a mixed market of preventive, therapeutic and personalized oncology tools, with the biggest upside tied to mRNA platforms, HPV policy expansion and combination cancer care.